RecruitingPhase 2NCT06177964
Lerapolturev (PVSRIPO) in GBM
Studying Malignant germ cell tumor of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Darell Bigner
- Principal Investigator
- Madison Shoaf, MDDuke University
- Intervention
- Lerapolturev(drug)
- Enrollment
- 92 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (1)
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
Istari Oncology, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06177964 on ClinicalTrials.govOther trials for Malignant germ cell tumor of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07519655Phase 1 Study of PF-08046033 in Advanced Solid TumorsPfizer
- RECRUITINGPHASE2NCT05483400Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsUniversity Medical Center Groningen
- ACTIVE NOT RECRUITINGNCT02724488Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic TherapiesUniversity Health Network, Toronto
See all trials for Malignant germ cell tumor of the cervix uteri →